Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

it has been barred by an old federal law from paying for weight-loss drugs. But last November Biden proposed new rules to allow Medicare and Medicaid to pay for these meds. The change would not ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Diabetes and weight loss drugs Ozempic ... the price of certain drugs with the companies that make them — was instituted following the Inflation Reduction Act of 2022, which President Joe ...